
Materials & Design, Journal Year: 2024, Volume and Issue: 246, P. 113356 - 113356
Published: Oct. 1, 2024
Language: Английский
Materials & Design, Journal Year: 2024, Volume and Issue: 246, P. 113356 - 113356
Published: Oct. 1, 2024
Language: Английский
Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(7), P. 2203 - 2203
Published: March 24, 2025
Recovery from traumatic spinal cord injury (tSCI) is challenging due to the limited regenerative capacity of central nervous system restore cells, myelin, and neural connections. At clinical level, fundamental pillars treatment are reduction in secondary damage (neuroprotection) rehabilitation; these tools we have mitigate disability caused by (SCI). To date, treatments on which neuroprotection has been based prevention acute respiratory failure avoid hypoxia, early hemodynamic control, neuroprotective drugs surgical management. Optimizing control ensure adequate perfusion may be key management SCI. While agents like methylprednisolone fallen into disuse, several promising therapies currently being tested trials. In terms treatment, although their impact neurological recovery remains debated, appropriate bone decompression followed duroplasty selected cases increasingly recommended. Advances cell hold significant potential for enhancing both functional outcomes SCI patients. Moreover, emerging neuromodulation techniques, such as transcutaneous epidural stimulation, along with innovations rehabilitation technologies-such robotic systems exoskeletons-are becoming indispensable improving locomotion overall mobility individuals This article provides an update advances against tSCI, cellular therapies, new therapies.
Language: Английский
Citations
0Phytotherapy Research, Journal Year: 2025, Volume and Issue: unknown
Published: April 2, 2025
Spinal cord injury (SCI) is a serious neurological disease with an extremely high disability rate. Most patients show loss of motor and sensory functions below the level injury. Current treatment protocols are based on early surgical decompression pharmacotherapy. However, efficacy these interventions suboptimal. Due to its complex pathophysiological mechanisms difficulty central nervous system (CNS) regeneration, exploring effective therapeutic remains daunting. Flavonoids secondary metabolites unique plants that have attracted attention in recent years for their potential now commonly used inflammation, tumors, other diseases. For SCI, related studies still exploring; some compounds, such as quercetin, fisetin, hesperetin, shown good anti-inflammatory anti-apoptotic properties, which help restore function injured spinal cord. flavonoids exhibit certain disadvantages, including poor solubility, low bioavailability, inability achieve long-term controlled release. Some proposed drug delivery strategies-including nanoparticles, hydrogels, collagen scaffolds-to enhance efficacy. In this paper, we summarize strategies SCI by searching relevant literature propose future research directions provide new ideas multimodal SCI.
Language: Английский
Citations
0Materials & Design, Journal Year: 2024, Volume and Issue: 246, P. 113356 - 113356
Published: Oct. 1, 2024
Language: Английский
Citations
0